The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant <i>Klebsiella pneumonia</i> with blaOXA-48-like Genes

• Main Authors: Al Maamon R. Abu Jaber (Author), Bilgen Basgut (Author), Ali Abdullah Hawan (Author), Ali Amer Al Shehri (Author), Sultan Ahmad AlKahtani (Author), Nehad J. Ahmed (Author), Abdikarim Abdi (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ceftazidime/avibactam (CAZ-AVI) is FDA-approved for managing infections caused by resistant gram-negative bacilli, particularly infections via carbapenem-resistant <i>Enterobacterales</i> pathogens. The clinical data are still limited, particularly those in Saudi Arabia. The present stud...